Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Frataxin pseudogene 1 (FXNP1) is a genomic DNA sequence similar to the functional frataxin gene (FXN), but lacks the ability to produce protein due to mutations or deletions that disrupt the coding region. Genuine frataxin (produced by the FXN gene) is crucial for mitochondrial iron-sulfur cluster biosynthesis, and mutations in the FXN gene cause Friedreich's ataxia, a neurodegenerative disease[1][5][3]. However, FXNP1 does not encode a protein, has no known biological function, and is not a receptor, enzyme, transporter, or other druggable target. It should not be used as a target in therapeutic research or biomarker development. Clarification: If your intention was to refer to the functional frataxin gene/protein (FXN) rather than FXNP1, please specify, as FXN is a well-established mitochondrial protein implicated in energy metabolism and Friedreich's ataxia[3][1][5][4]. FXNP1, as a pseudogene, should be excluded from structured drug target databases and resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Frataxin pseudogene 1 (FXNP1).